Evidence map›Paper›PMID 29343804›Full record

ArticleEuropean journal of human genetics : EJHG2018

Compound heterozygous SPATA5 variants in four families and functional studies of SPATA5 deficiency.

Sanna Puusepp, Reka Kovacs-Nagy, Bader Alhaddad, Matthias Braunisch, Georg F Hoffmann, Urania Kotzaeridou, Lucia Lichvarova, Mailis Liiv, Christine Makowski, Merle Mandel and 11 more

Open access · hybridAbstract readCase Reports
In one paragraph

Article in European journal of human genetics : EJHG, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Ribosome biogenesis and function in development and disease.Development (Cambridge, England) · 2023
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 8 institutions in 4 countries.

Sanna PuuseppDepartment of Clinical Genetics, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.
Reka Kovacs-NagyInstitute of Human Genetics, Technische Universität München, Munich, Germany.
Bader AlhaddadInstitute of Human Genetics, Technische Universität München, Munich, Germany.ORCID http://orcid.org/0000-0003-4542-5267
Matthias BraunischInstitute of Human Genetics, Technische Universität München, Munich, Germany.
Georg F HoffmannCenter for Child and Adolescent Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Urania KotzaeridouCenter for Child and Adolescent Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Lucia LichvarovaDepartment of Pharmacology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Mailis LiivDepartment of Pharmacology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Christine MakowskiDepartment of Pediatrics, Technical University Munich, Munich, Germany.
Merle MandelDepartment of Pharmacology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Thomas MeitingerInstitute of Human Genetics, Technische Universität München, Munich, Germany.
Sander PajusaluDepartment of Clinical Genetics, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.ORCID http://orcid.org/0000-0002-5435-0781
Richard J RodenburgRadboud Center for Mitochondrial Medicine, Translational Metabolic Laboratory, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0001-5227-3527
Dzhamilja SafiulinaDepartment of Pharmacology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Tim M StromInstitute of Human Genetics Helmholz-Zentrum München, Munich, Germany.
Inga TalvikTallinn Children's Hospital, Tallinn, Estonia.
Annika VaarmannDepartment of Pharmacology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Callum WilsonNational Metabolic Service, Auckland City Hospital, Auckland, New Zealand.
Allen KaasikDepartment of Pharmacology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Tobias B HaackInstitute of Human Genetics, Technische Universität München, Munich, Germany.
Katrin ÕunapDepartment of Clinical Genetics, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia. katrin.ounap@kliinikum.ee.
University of Tartu · EETechnical University of Munich · DEHelmholtz Zentrum München · DETartu University Hospital · EEHeidelberg University · DEAuckland City Hospital · NZRadboud University Nijmegen · NLTallinn Health Care College · EE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Variants in the SPATA5 gene were recently described in a cohort of patients with global developmental delay, sensorineural hearing loss, seizures, cortical visual impairment and microcephaly. SPATA5 protein localizes predominantly in the mitochondria and is proposed to be involved in mitochondrial function and brain developmental processes. However no functional studies have been performed. This study describes five patients with psychomotor developmental delay, microcephaly, epilepsy and hearing impairment, who were thought clinically to have a mitochondrial disease with subsequent whole-exome sequencing analysis detecting compound heterozygous variants in the SPATA5 gene. A summary of clinical data of all the SPATA5 patients reported in the literature confirms the characteristic phenotype. To assess SPATA5's role in mitochondrial dynamics, functional studies were performed on rat cortical neurons. SPATA5-deficient neurons had a significant imbalance in the mitochondrial fusion-fission rate, impaired energy production and short axons. In conclusion, SPATA5 protein has an important role in mitochondrial dynamics and axonal growth. Biallelic variants in the SPATA5 gene can affect mitochondria in cortical neurons and should be considered in patients with a neurodegenerative disorder and/or with clinical presentation resembling a mitochondrial disorder.

Indexed as

Mitochondrial DynamicsAnimalsATPases Associated with Diverse Cellular ActivitiesCells, CulturedChildChild, PreschoolDevelopmental DisabilitiesEnergy MetabolismEpilepsyFemaleHeterozygoteHumansMaleMicrocephalyNeuronsRatsATPases Associated with Diverse Cellular ActivitiesSPATA5 protein, human

Identifiers

PMID29343804
PMCPMC5838984
OpenAlexW2789679765

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.